Oncology & Cancer

NICE says 'not enough data' to approve drug for ovarian cancer

The National Institute for Health and Care Excellence (NICE) says it cannot give a positive decision over whether to recommend a new drug for ovarian cancer unless its makers provide more information on cost. A final decision ...

page 6 from 6